HYTN Receives GMP Certificates for The United States, Bermuda and Israel
Source: HYTN Innovations Inc.
April 02, 2025 20:00 ET
HYTN Receives GMP
Certificates for The United
States, Bermuda and Israel
VANCOUVER, British Columbia, April 02, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:
HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a leader in pharmaceutical-grade
cannabis manufacturing, is pleased to announce that it has received digital Good Manufacturing
Practices (GMP) certicates (the “Certicates”) from Health Canada, conrming the GMP
compliance of its Kelowna-based manufacturing facility. Issued under HYTN’s Drug Establishment
Licence (“DEL”), these Certicates specically acknowledge the Company’s GMP status for the
United States, Bermuda, and Israel.
The Certicates, requested by HYTN in February, are important for drug registrations in jurisdictions
where they apply. They also provide assurance in regions with limited regulatory frameworks,
validating that HYTN’s production processes meet GMP standards. Notably, the Company’s DEL
enables it to fabricate, package, and label non-sterile pharmaceuticals containing cannabis and
psilocybin, positioning HYTN at the forefront of international markets looking to expand their
pharmaceutical offerings.
“By demonstrating GMP compliance in markets that require it, HYTN is well-positioned to support
new drug registrations, facilitate clinical trials, and offer contract manufacturing for both cannabis
and psilocybin-based pharmaceuticals,” said Jason Broome, COO of HYTN. “Our continued
commitment to GMP manufacturing strengthens our ability to evaluate global opportunities while
driving value for partners and stakeholders alike.”
While HYTN is already active in commercial projects across Canada, the UK, Germany and Australia,
the Company is also exploring expansions into additional markets. Securing GMP Certicates for
the U.S., Bermuda, and Israel underscores HYTN’s progress in advancing GMP drug development
and reafrms its leadership in high-quality, compliant manufacturing practices to fuel international
growth.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing,
marketing, and sale of products containing psychoactive and psychotropic compounds, including
cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming
a premier provider of these products across all federally regulated markets. The Company
accomplishes this by strategically identifying market opportunities and effectively bringing
innovative products to market through its advanced development platform.
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that
a manufactured product is safe for human consumption or use. Many countries have legislated that
manufacturers follow GMP procedures and create their own GMP guidelines that correspond with
their legislation.
For more information contact:
Elliot McKerr
Chief Executive Ofcer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
Forward-Looking Statements Disclaimer
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents
of this press release.
Certain information contained herein may constitute forward-looking information involving risks
and uncertainties. Readers are cautioned not to place undue reliance on forward-looking
statements, including, but not limited to, statements regarding the Company's GMP certication
and its potential to facilitate drug registrations, global expansions, clinical trials, and contract
manufacturing opportunities. Factors that could cause actual results to differ materially from
forward-looking statements or that may affect the operations, performance, development, and
results of the Company's business include, among other things: challenges or delays in international
regulatory approvals; inability to maintain or comply with GMP standards; failure to secure or
maintain necessary partnerships and relationships; inability to successfully expand into new
jurisdictions; competitive pressures and market acceptance of the Company's products and
services; regulatory changes impacting operations; and general economic and business conditions.
Any statements that are not statements of historical fact are deemed forward-looking statements.
The forward-looking statements contained in this press release are made as of the date of this press
release, and except to the extent required by applicable law, the Company assumes no obligation
to update or revise forward-looking statements herein or otherwise, whether due to new
information, future events, or otherwise. The forward-looking statements contained in this press
release are expressly qualied by this cautionary note.
